Romiplostim: A review of its use in immune thrombocytopenia

Drugs

Volumn 72, Issue 3, 2012, Pages 415-435

  Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Idiopathic thrombocytopenic purpura; Immune thrombocytopenic purpura; Romiplostim

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DANAZOL; ELTROMBOPAG; IMMUNOGLOBULIN; RITUXIMAB; ROMIPLOSTIM;

ADJUVANT THERAPY; ARTERY THROMBOSIS; ARTHRALGIA; BLEEDING; BLOOD CELL COUNT; BLOOD SMEAR; BONE MARROW BIOPSY; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTUSION; COUGHING; CROSS REACTION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; ECCHYMOSIS; EMOTIONAL STABILITY; EPISTAXIS; FATIGUE; FOLLOW UP; FOOD DRUG INTERACTION; GINGIVA BLEEDING; HEADACHE; HEALTH; HEMATOLOGIC MALIGNANCY; HEMATOMA; HUMAN; IMMUNE THROMBOCYTOPENIA; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE CONTUSION; INJECTION SITE HEMATOMA; INSOMNIA; INTERMETHOD COMPARISON; LIMIT OF QUANTITATION; LONG TERM CARE; LUNG EMBOLISM; MEDICAL CARE; MENORRHAGIA; METRORRHAGIA; MULTICENTER STUDY (TOPIC); NAUSEA; ORAL BLISTER; PAIN; PATIENT SAFETY; PETECHIA; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REPRODUCTIVE HEALTH; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SOCIAL BEHAVIOR; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WORK;

BLOOD PLATELETS; HUMANS; INJECTIONS, SUBCUTANEOUS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECEPTORS, THROMBOPOIETIN; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856754654     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208260-000000000-00000     Document Type: Review

References (64)

1. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011 Apr 21; 117 (16): 4190-207
2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009 Mar 12; 113 (11): 2386-93
3. Provan D, StasiR,Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010 Jan 14; 115 (2): 168-86
4. Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol 2007 Sep; 14 (5): 515-9 (Pubitemid 47457643)
5. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol 2009 Apr; 145 (2): 235-44
6. Michel M. Immune thrombocytopenic purpura: epidemiology and implications for patients. Eur J Haematol 2009; 82 Suppl. 71: 3-7
7. Godeau B, Michel M. Treatment of chronic immune thrombocytopenic purpura in adults. Ann Hematol 2010 Apr 14; 89 Suppl. 1: S55-60
8. Cines DB, McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol 2007 Sep; 14 (5): 511-4 (Pubitemid 47457642)
9. Cines DB, Bussel JB, Liebman HA. The ITP syndrome: pathogenic and clinical diversity. Blood 2009 Jun 25; 113 (26): 6511-21
10. Nugent D, McMillan R, Nichol JL, et al. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146 (6): 585-96
11. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006 May 11; 354 (19): 2034-45
12. Chouhan JD, Herrington JD. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag. Pharmacotherapy 2010 Jul; 30 (7): 666-83
13. European Medicines Agency. Nplate (romiplostim): EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-li brary/EPAR-Product-Information/human/000942/WC 500039537.pdf [Accessed 2011 Dec 21]
14. Molineux G, Newland A. Development of romiplostim for the treatment of patients with chronic immune thrombocytopenia: from bench to bedside. Br J Haematol 2010 Jul; 150 (1): 9-20
15. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004 Dec; 76 (6): 628-38 (Pubitemid 39601552)
16. Ipema HJ, Jung MY, Lodolce AE. Romiplostim management of immune thrombocytopenic purpura. Ann Pharmacother 2009 May; 43 (5): 914-9
17. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004 Jan 21; 25 (2): 52-60 (Pubitemid 38018897)
18. Kumagai Y, Fujita T, Ozaki M, et al. Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesisstimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 2007 Dec; 47 (12): 1489-97 (Pubitemid 350115297)
19. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006 Nov; 135 (4): 547-53 (Pubitemid 44583422)
20. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl JMed 2006 Oct 19; 355 (16): 1672-81 (Pubitemid 44583957)
21. Shirasugi Y, Ando K, Hashino S, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol 2009 Sep; 90 (2): 157-65
22. Wang Y-MC, Krzyzanski W, Doshi S, et al. Pharmacodynamics- mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J 2010 Dec; 12 (4): 729-40
23. Wang Y-MC, Sloey B, Wong T, et al. Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. PharmRes 2011 Aug; 28 (8): 1931-8
24. Amgen Inc. Nplate- (romiplostim) for subcutaneous injection: US prescribing information [online]. Available from URL: http://pi.amgen.com/ united-states/nplate/nplate- pi-hcp-english.pdf [Accessed 2011 Dec 21]
25. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008 Feb 2; 371 (9610): 395-403 (Pubitemid 351181334)
26. Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial. Int J Hematol 2011 Jul; 94 (1): 71-80
27. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010 Nov 11; 363 (20): 1889-99
28. Pullarkat VA, Gernsheimer TB, Wasser JS, et al. Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). Am J Hematol 2009; 84 (8): 538-40
29. Michel M, te Boekhorst PAW, Janssens A, et al. Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology 2011 Sep; 16 (5): 274-7
30. George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 2009 Feb; 144 (3): 409-15
31. Sanz MA, Aledort L, Mathias SD, et al. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health 2011 Jan; 14 (1): 90-6
32. Bussel JB, Kuter DJ, Pullarkat V, et al. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009Mar 5; 113 (10): 2161-71
33. Kuter J, Newland A, Bussel J, et al. Evaluation of efficacy and safety of long-term romiplostim treatment for patients with immune thrombocytopenia (ITP) enrolled in an openlabel extension study: a patient cohort-analysis [abstract no. 0189]. Haematologica 2010; 95 Suppl. 2: 76
34. Kuter DJ, Bussel JB, Newland A, et al. Long-term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP): final report from an open-label extension study [abstract no. 68]. 52nd Annual Meeting and Exposition of the American Society of Hematology; 2010 Dec 4-7; Orlando (FL)
35. Miyazaki K, Shirashugi Y, Ando K, et al. An open-label extension study evaluating the safety and efficacy of up to 3.5 years of romiplostim in thrombocytopenic Japanese patients with chronic immune thrombocytopenic purpura (ITP) [abstract no. 0229]. Haematologica 2011; 96 Suppl. 2: 94-5
36. Mathias S, George J, Aledort L, et al. Health-related quality of life (HRQOL) in chronic immune thrombocytopenia (ITP) patients: results from a long-term study of romiplostim [abstract no. 0792]. Haematologica 2011; 96 Suppl. 2: 329-30
37. Wasser J, Boccia RVV, Lyons RM, et al. Use of rituximab in a study comparing the thrombopoietin mimetic romiplostim with standard of care (SOC) in patients with immune thrombocytopenia (ITP) [abstract no. 3282 plus poster]. 53rd Annual Meeting and Exposition of the American Society of Hematology; 2011 Dec 9-13; San Diego (CA)
38. Boccia R, Kuter DJ, Rummel MJ, et al. The effects of romiplostim or standard of care (SOC) on splenectomy and treatment failure of patients who had immune thromobocytopenia (ITP) for less than or equal to one year [abstract no. 3702]. 52nd AnnualMeeting and Exposition of the American Society of Hematology; 2010 Dec 4-7; Orlando (FL)
39. Lyons RM, Boccia RV, Macik G, et al. Home administration of romiplostim by patients with chronic immune thrombocytopenia (ITP) [abstract no. 3510]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5-7; New Orleans (LA)
40. Janssens A, Tarantino MD, Bird R, et al. Final results from an international, multi-center, single-arm study evaluating the safety and efficacy of romiplostim in adults with primary immune thrombocytopenia (ITP) [abstract no. 3279 plus poster]. 53rd AnnualMeeting and Exposition of theAmerican Society of Hematology; 2011 Dec 9-13; San Diego (CA)
41. KhellafM,MichelM, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionateuse program. Blood 2011 Oct 20; 118 (16): 4338-45
42. Gernsheimer TB, George JN, Aledort LM, et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8 (6): 1372-82
43. Rodeghiero F, Provan D, Cines D, et al. Safety analysis of long-term romiplostim use in patients with chronic immune thrombocytopenia (ITP) [abstract]. 15th Congress of the European Hematology Association; 2010 Jun 10-13; Barcelona
44. Jawa V, Hokom M, Hu Z, et al. Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Ann Hematol 2010; 89 Suppl. 1: S75-85
45. Kuter DJ, Mufti GJ, Bain BJ, et al. Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. Blood 2009 Oct 29; 114 (18): 3748-56
46. BestPractice. Idiopathic thromobcytopenic purpura [online]. Available from URL: http://bestpractice.bmj.com/best-practice/monograph/138/treatment.html [Accessed 2011 Sep 16]
47. Bussel JB, Rodeghiero F, Lyons RM, et al. Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases [abstract no. 3281 plus poster]. 53rd Annual Meeting and Exposition of the American Society of Hematology; 2011 Dec 9-13; San Diego (CA)
48. Newland A, Cervinek L, Eggermann J, et al. Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim: four European case studies [abstract no. 0237]. Haematologica 2011; 96 Suppl. 2: 98
49. Cuker A, Cines DB. Immune thrombocytopenia. Hematology Am Soc Hematol Educ Program 2010; 2010 (1): 377-84
50. Cuker A, Chiang EY, Cines DB. Safety of the thrombopoiesis- stimulating agents for the treatment of immune thrombocytopenia. Curr Drug Saf 2010 Apr; 5 (2): 171-81
51. Dultz G, Kronenberger B, Azizi A, et al. Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. J Hepatol 2011 Jul; 55 (1): 229-32
52. Amgen. A prospective study evaluating changes in bone marrow morphology in adult subjects receiving romiplostim for the treatment of thrombocytopenia associated with immune (idiopathic) thrombocytopenic purpura (ITP) [Clinical- Trials.gov identifier NCT00907478]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Sep 16]
53. Pettigrew M, Deuson R, Garces K. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Quebec [abstract no. 4211]. 53rd Annual Meeting and Exposition of the American Society of Hematology; 2011 Dec 9-13; San Diego (CA)
54. Arocho R, Northridge K, Rivera Hurtado R, et al. A pharmacoeconomic evaluation of romiplostim (Nplate-) for the treatment of chronic immune thrombocytopenia (ITP) in Mexico [abstract plus poster]. 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2011 May 21-25; Baltimore (MD)
55. Brosa M, Arocho R, Gutierrez L, et al. A pharmacoeconomic evaluation of romiplostim (Nplate-) for the treatment of chronic immune thrombocytopenia (ITP) [abstract plus poster]. 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2010 Nov 6-9; Prague
56. Chiche L, Lefrere F, Chulikavit M, et al. Cost-consequence analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia (ITP) in France [abstract plus poster]. 14th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2011 Nov 5-8; Madrid
57. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011 Jul 7; 118 (1): 28-36
58. Amgen. Safety and efficacy study of romiplostim to treat ITP in pediatric subjects [ClinicalTrials.gov identifier NCT01444417]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: http://www. clinicaltrials.gov [Accessed 2012 Jan 25]
59. European Medicines Agency. Revolade (eltrombopag): EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/doc ument-library/EPAR-Product-Information/human/001110/WC500089964.pdf [Accessed 2011 Jul 27]
60. GlaxoSmithKline. Promacta- (eltrombopag) tablets for oral use: US prescribing information [online]. Available from URL: http://us.gsk.com/ products/assets/us-promacta. pdf [Accessed 2011 Aug 3]
61. Zeng Y, Duan X, Xu J, et al. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011; 7: CD008235
62. Garnock-Jones KP. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs 2011; 71 (10): 1333-53
63. National Institute for Health and Clinical Excellence. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/13467/54219/54219.pdf [Accessed 2011 Jul 27]
64. National Institute for Health and Clinical Excellence. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura [online]. Available from URL: http://www.nice.org.uk/nicemedia/live/13250/51269/51269.pdf [Accessed 2011 Jul 27]